Search

Eurofins Scientific SE

Open

70.64 -0.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

70.5

Max

71.36

Schlüsselkennzahlen

By Trading Economics

Einkommen

123M

Verkäufe

1.8B

KGV

Branchendurchschnitt

31.683

23.145

Dividendenrendite

0.83

Gewinnspanne

6.827

Angestellte

65,000

EBITDA

409M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+4.73% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.83%

4.30%

Nächstes Ergebnis

25. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

13B

Vorheriger Eröffnungskurs

71.06

Vorheriger Schlusskurs

70.64

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Eurofins Scientific SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Jan. 2026, 21:55 UTC

Ergebnisse

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. Jan. 2026, 23:52 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. Jan. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. Jan. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Jan. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. Jan. 2026, 22:37 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. Jan. 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

22. Jan. 2026, 21:44 UTC

Ergebnisse

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. Jan. 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. Jan. 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. Jan. 2026, 21:30 UTC

Ergebnisse

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One To Acquire Brex >COF

22. Jan. 2026, 21:13 UTC

Ergebnisse

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. Jan. 2026, 21:11 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. Jan. 2026, 21:10 UTC

Ergebnisse

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. Jan. 2026, 21:06 UTC

Ergebnisse

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Rev $15.58B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q EPS $3.26 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Interest Margin 8.26% >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net $2.13B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Adj EPS $3.86 >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Capital One 4Q Net Charge-Offs $3.8B >COF

22. Jan. 2026, 21:05 UTC

Ergebnisse

Intuitive Surgical 4Q EPS $2.21 >ISRG

Eurofins Scientific SE Prognose

Kursziel

By TipRanks

4.73% Vorteil

12-Monats-Prognose

Durchschnitt 73.33 EUR  4.73%

Hoch 81 EUR

Tief 64 EUR

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eurofins Scientific SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

54.22 / 56.82Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
help-icon Live chat